Currently out of the existing stock ratings of Paul Knight, 138 are a BUY (90.2%), 15 are a HOLD (9.8%).

Paul Knight

Work Performance Price Targets & Ratings Chart

Analyst Paul Knight, currently employed at KEYBANK, carries an average stock price target met ratio of 53.52% that have a potential upside of 37.3% achieved within 160 days.

Paul Knight’s has documented 302 price targets and ratings displayed on 28 stocks. The coverage is on Healthcare, Basic Materials, Technology, Industrials sectors.

Most recent stock forecast was given on XGN, Exagen at 11-Mar-2026.

Wall Street Analyst Paul Knight

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for CYRX (CRYOPORT) at 1/19/2021. The price target of $75 was fulfilled within 3 days with a profit of $10.82 (16.86%) receiving and performance score of 56.2.

Average potential price target upside

of $73.48 (27.58%) on WST (WEST PHARMACEUTICAL SERVICES).
of $70.31 (42.57%) on RGEN (REPLIGEN).
of $65.94 (14.07%) on TMO (THERMO FISHER SCIENTIFIC).

A Agilent Technologies AVTR Avantor BRKS Brooks Automation CDMO Avid Bioservices CYRX Cryoport DNAY Codex DNA HBIO Harvard Bioscience TMO Thermo Fisher Scientific VCYT Veracyte BLFS BioLife Solutions CSTL Castle Biosciences CTLT Catalent DHR Danaher MRVI Maravai Lifesciences Holdings RGEN Repligen STVN Stevanato Group SpA TECH Bio-Techne Corp OCX OncoCyte Corp WST West Pharmaceutical Services XGN Exagen AZTA Azenta PKI PerkinElmer LAB Standard Biotools RVTY Revvity FLDM Fluidigm WAT Waters TKNO Alpha Teknova MLAB Mesa Laboratories

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Luke Sergott (BARCLAYS)